Form 4: SOPHiA GENETICS Officer Sells Shares

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported the sale of ordinary shares valued at approximately $13,130 to cover tax withholding obligations.

Summary

• Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold a total of 5,100 ordinary shares on April 6th and 7th, 2026.
• The sales were conducted to satisfy tax withholding obligations related to the vesting of restricted stock units.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating they were not discretionary.
• The total value of the shares sold was approximately $24,600, with the weighted average sale price for the first transaction being $4.85 and for the second transaction being $4.865.
• Following these sales, Philippe Menu beneficially owns 281,452 ordinary shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the sale of shares by a key executive, despite the transactions being conducted under a pre-arranged plan for tax purposes.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which is a pre-arranged plan designed to avoid insider trading concerns.
• The transactions were for the purpose of covering tax withholding obligations, a common and expected event for executives upon vesting of equity awards.

Negatives

• A significant number of shares (5,100) were sold by a key executive.
• The sales represent a reduction in the Chief Medical Officer's direct beneficial ownership of the company's stock.

Risks

• Potential for negative market perception due to insider selling, even if conducted under a pre-arranged plan.
• The tax withholding obligations suggest that the value of vested equity awards is substantial, but the sale of shares to cover these obligations reduces the executive's direct stake.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on past transactions.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can sometimes be interpreted negatively by the market, regardless of the underlying reasons like tax obligations. This is a common disclosure for executives in the biotechnology and healthcare technology sectors.

Stakeholder Impact

• Shareholders: May perceive insider selling as a negative signal, potentially impacting short-term stock price, although the Rule 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees: The sale is related to executive compensation and tax obligations, with no direct impact on other employees.
• Management: Demonstrates adherence to tax obligations and pre-defined trading plans.

Next Steps

• The reporting person will continue to hold 281,452 ordinary shares.
• Further transactions, if any, will be reported on subsequent SEC filings.

Key Dates

Recommendation

The filing reports routine share sales by an executive to cover tax obligations under a pre-established 10b5-1 plan. While insider selling can be a negative signal, the structured nature of these sales and the stated purpose suggest it is not indicative of a lack of confidence in the company's future prospects. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of the company's performance.

Keywords

SOPHiA GENETICS SA, SOPH, Form 4, Insider Trading, Share Sale, Philippe Menu, Chief Medical Officer, Rule 10b5-1, Tax Withholding, Restricted Stock Units, Beneficial Ownership